Searching for New Ways to Fight Bacterial Resistance
Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections, including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (RifR). As resistance mechanisms found in clinical settings may also occur in natural environments, researchers postulated that bacteria could have evolved to produce rifamycin congeners active against clinically relevant resistance phenotypes.
A survey of soil metagenomes identified a tailoring enzyme-rich family of gene clusters encoding biosynthesis of rifamycin congeners (kanglemycins, Kangs) with potent in vivo and in vitro activity against the most common clinically relevant RifR mutations. Structural and mechanistic analyses revealed the basis for Kang inhibition of RifR RNAP. Unlike Rifs, Kangs function through a mechanism that includes interfering with 5′-initiating substrate binding.
The results suggest that examining soil microbiomes for new analogues of clinically used antibiotics may uncover metabolites capable of circumventing clinically important resistance mechanisms.
J. Peek, M. Lilic, D. Montiel, A. Milshteyn, I. Woodworth, J. B. Biggins, M. A. Ternei, P. Y. Calle, M. Danziger, T. Warrier, K. Saito, N. Braffman, A. Fay, M. S. Glickman, S. A. Darst, E. A. Campbell, S. F. Brady. “Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism” Nature Communications 9, 4147 (2018). DOI: 10.1038/s41467-018-06587-2